Nicotine (2 mg) — Competitive Intelligence Brief

Nicotine (2 mg) (Nicotine (2 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine (2 mg) (Nicotine (2 mg)) — GlaxoSmithKline. Nicotine binds to nicotinic acetylcholine receptors in the brain and peripheral nervous system, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine (2 mg) TARGET	Nicotine (2 mg)	GlaxoSmithKline	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine polacrilex lozenge	Nicotine polacrilex lozenge	University of Maryland, Baltimore	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Standard Duration Combination NRT	Standard Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy combination	Nicotinic acetylcholine receptors
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class